Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …

Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-
severe atopic dermatitis exists. We sought to reach international consensus through an …

Introduction Rheumatoid arthritis (RA) is a chronic disabling disease characterized by a
symmetrical articular involvement due to ongoing joint inflammation, if left insufficiently …

To update the European League Against Rheumatism (EULAR) recommendations for the
role of the nurse in the management of chronic inflammatory arthritis (CIA) using the most up …

Background To date, head-to-head trials comparing the efficacy and safety of biological
disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in …

Objectives To investigate how the first wave of COVID-19 pandemic influenced decisions of
rheumatologists and health professionals in rheumatology regarding the management of …

Objective We developed a smartphone application for patients with rheumatoid arthritis (RA)
that allows them to self‐monitor their disease activity in between clinic visits by answering a …

Fibromyalgia (FM) is one of the most common conditions that rheumatologists encounter. It
is characterised by chronic widespread pain, fatigue, sleep disturbances and impaired …

Sustained remission is an ultimate treatment goal in the management of patients with
rheumatoid arthritis (RA). Historically the frequency of sustained remission was low but the …

Objective To test the effect of patient‐reported outcome (PRO)–based tele‐health followup
for tight control of disease activity in patients with rheumatoid arthritis (RA), and the …